首页> 外文期刊>Drugs - Real World Outcomes >Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia
【24h】

Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia

机译:同时使用选择性5-羟色胺再摄取抑制剂和其他精神药物的老年人髋部骨折的风险:澳大利亚的一项病例对照研究

获取原文
       

摘要

BackgroundFew studies have assessed the risk of hip fracture following concurrent use of psychoactive medicines, and none has investigated combinations with selective serotonin reuptake inhibitors. ObjectivesTo assess the risk of hip fracture in older people as a result of concurrent use of selective serotonin reuptake inhibitors and other psychoactive medicines. MethodsA matched case–control design was employed. Cases were Australian Government Department of Veterans’ Affairs beneficiaries aged over 65?years who experienced a hip fracture between 2009 and 2012. Each case was matched with up to four randomly selected controls of the same age (±2?years) and sex. Medicine-hip fracture associations were estimated via conditional logistic regression. The relative excess risk due to interaction (RERI) was calculated to determine whether combined effects differed from the sum of individual effects. ResultsThere were 8828 cases and 35,310 controls. The median age of subjects was 88?years and 63% were women. The risk of hip fracture was elevated for all medicines assessed individually, most notably selective serotonin reuptake inhibitors (initiation: odds ratio [OR]?=?2.7, 95% confidence interval [CI] 2.1, 3.6) and opioids (initiation: OR?=?2.3, 95% CI 1.9, 2.9). Combinations associated with an increased odds of hip fracture included addition of benzodiazepines to selective serotonin reuptake inhibitor therapy (OR?=?3.0, 95% CI 1.9, 4.8; RERI?=?0.9, 95% CI ?0.5, 2.3), concurrent use of both opioids and selective serotonin reuptake inhibitors (OR?=?2.2, 95% CI 1.9, 2.6; RERI?=?0.1, 95% CI ?0.3, 0.5), addition of opioids to selective serotonin reuptake inhibitor therapy (OR?=?3.2, 95% CI 1.8, 5.5; RERI?=??0.1, 95% CI ?2.0, 1.7), and initiation of both benzodiazepines and selective serotonin reuptake inhibitors (OR?=?4.7, 95% CI 1.7, 13; RERI?=?1.3, 95% CI ?3.8, 6.3). The RERI results suggested that the effect of each of these medicine combinations equalled the sum of the effects of individual medicine use. ConclusionsIn older people, the concurrent use of selective serotonin reuptake inhibitors and other psychoactive medicines increased the risk of hip fracture as much as the sum of the risks owing to individual medicine use. Our results highlight the need for prescribers to consider the sedative burden of medicines in each older patient as well as the potential for an additive risk of hip fracture when initiating additional psychoactive therapy.
机译:背景很少有研究评估并用精神活性药物后发生髋部骨折的风险,没有研究评估与选择性5-羟色胺再摄取抑制剂的组合。目的评估同时使用选择性5-羟色胺再摄取抑制剂和其他精神药物导致老年人髋部骨折的风险。方法采用匹配的病例对照设计。病例为澳大利亚政府退伍军人事务部受益人,年龄在65岁以上,2009年至2012年之间发生了髋部骨折。每例均与多达四个随机选择的年龄和性别相同的对照组相匹配。通过条件逻辑回归估计药物-髋关节骨折的关联。计算了由于相互作用引起的相对超额风险(RERI),以确定组合效应是否不同于单个效应的总和。结果共有8828例病例和35310例对照者。受试者的中位年龄为88岁,女性为63%。单独评估的所有药物,尤其是选择性5-羟色胺再摄取抑制剂(初始值:比值比[OR]?=?2.7,95%置信区间[CI] 2.1,3.6)和阿片类药物(初始值:OR?)的髋部骨折风险均升高。 =?2.3,95%CI 1.9,2.9)。与髋部骨折几率增加相关的组合包括在选择性5-羟色胺再摄取抑制剂治疗中加入苯二氮卓类药物(ORα=?3.0,95%CI 1.9,4.8; RERI?=?0.9,95%CI?0.5,2.3),同时使用类阿片和选择性5-羟色胺再摄取抑制剂(OR?=?2.2,95%CI 1.9,2.6;RERIα=?0.1,95%CI?0.3,0.5),将阿片类药物加入选择性5-羟色胺再摄取抑制剂治疗(OR?= <3.2,95%CI为1.8,5.5; RERI = 0.1,95%CI为2.0,1.7),并同时引发苯二氮卓类和选择性5-羟色胺再摄取抑制剂(OR == 4.7,95%CI 1.7,13。 RERI≥1.3,95%CI≥3.8,6.3)。 RERI结果表明,每种药物组合的效果等于单个药物使用效果的总和。结论在老年人中,同时使用选择性5-羟色胺再摄取抑制剂和其他精神活性药物会增加髋部骨折的风险,与单独使用药物引起的风险之和一样多。我们的结果突出表明,处方者需要在每位年龄较大的患者中考虑镇静药物的负担,以及在开始其他心理治疗时可能会增加髋部骨折的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号